Literature DB >> 20878453

Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM.

K J F Petersson1, L E Friberg, M O Karlsson.   

Abstract

Computer models of biological systems grow more complex as computing power increase. Often these models are defined as differential equations and no analytical solutions exist. Numerical integration is used to approximate the solution; this can be computationally intensive, time consuming and be a large proportion of the total computer runtime. The performance of different integration methods depend on the mathematical properties of the differential equations system at hand. In this paper we investigate the possibility of runtime gains by calculating parts of or the whole differential equations system at given time intervals, outside of the differential equations solver. This approach was tested on nine models defined as differential equations with the goal to reduce runtime while maintaining model fit, based on the objective function value. The software used was NONMEM. In four models the computational runtime was successfully reduced (by 59-96%). The differences in parameter estimates, compared to using only the differential equations solver were less than 12% for all fixed effects parameters. For the variance parameters, estimates were within 10% for the majority of the parameters. Population and individual predictions were similar and the differences in OFV were between 1 and -14 units. When computational runtime seriously affects the usefulness of a model we suggest evaluating this approach for repetitive elements of model building and evaluation such as covariate inclusions or bootstraps.

Mesh:

Year:  2010        PMID: 20878453     DOI: 10.1007/s10928-010-9169-x

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  9 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations.

Authors:  Hanna E Silber; Petra M Jauslin; Nicolas Frey; Ronald Gieschke; Ulrika S H Simonsson; Mats O Karlsson
Journal:  J Clin Pharmacol       Date:  2007-09       Impact factor: 3.126

3.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

4.  Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.

Authors:  I F Trocóniz; T H Naukkarinen; H M Ruottinen; U K Rinne; A Gordin; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  1998-07       Impact factor: 6.875

5.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

6.  A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.

Authors:  Jakob Ribbing; Bengt Hamrén; Maria K Svensson; Mats O Karlsson
Journal:  J Clin Pharmacol       Date:  2010-05-19       Impact factor: 3.126

7.  An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers.

Authors:  Anna Lönnebo; Anders Grahnén; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

8.  Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.

Authors:  B Hamrén; E Björk; M Sunzel; Mo Karlsson
Journal:  Clin Pharmacol Ther       Date:  2008-03-19       Impact factor: 6.875

9.  An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.

Authors:  L E Friberg; A M Vermeulen; K J F Petersson; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2008-12-24       Impact factor: 6.875

  9 in total
  1 in total

1.  Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models.

Authors:  Xu Steven Xu; Hui Wang; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-31       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.